- Home
- APLT vs CRIS Comparison
APLT vs CRIS Comparison
Compare APLT & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APLT | CRIS |
|---|---|---|
| Founded | 2016 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.0M | 14.6M |
| IPO Year | 2019 | 2000 |
Fundamental Metrics
Financial Performance| Metric | APLT | CRIS |
|---|---|---|
| Price | $0.11 | $1.06 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $1.25 | ★ $16.50 |
| AVG Volume (30 Days) | ★ 9.9M | 114.9K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,000,000.00 | ★ $11,650,000.00 |
| Revenue This Year | $124.18 | $6.13 |
| Revenue Next Year | $66.67 | $7.86 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.56 |
| 52 Week Low | $0.10 | $1.02 |
| 52 Week High | $1.50 | $4.50 |
Technical Indicators
Market Signals| Indicator | APLT | CRIS |
|---|---|---|
| Relative Strength Index (RSI) | 25.98 | 36.38 |
| Support Level | $0.10 | $1.02 |
| Resistance Level | $0.13 | $1.41 |
| Average True Range (ATR) | 0.02 | 0.08 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 7.66 | 10.28 |
Price Performance
Historical ComparisonAbout APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.